Currently, there are 257.47M common shares owned by the public and among those 256.91M shares have been available to trade.
The company’s stock has a 5-day price change of -7.79% and -13.60% over the past three months. OGN shares are trading 14.15% year to date (YTD), with the 12-month market performance up to 23.76% higher. It has a 12-month low price of $10.84 and touched a high of $23.10 over the same period. OGN has an average intraday trading volume of 2.07 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.80%, -14.02%, and -14.90% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Organon & Co (NYSE: OGN) shares accounts for 80.32% of the company’s 257.47M shares outstanding.
It has a market capitalization of $4.24B and a beta (3y monthly) value of 0.80. The stock’s trailing 12-month PE ratio is 3.26, while the earnings-per-share (ttm) stands at $5.04. The company has a PEG of 0.68 and a Quick Ratio of 1.21 with the debt-to-equity ratio at 17.75. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.46% over the week and 2.70% over the month.
Earnings per share for the fiscal year are expected to decrease by -0.35%, and 2.53% over the next financial year. EPS should grow at an annualized rate of 4.83% over the next five years, compared to -14.04% over the past 5-year period.
Looking at the support for the OGN, a number of firms have released research notes about the stock. JP Morgan stated their Underweight rating for the stock in a research note on September 06, 2024, with the firm’s price target at $18-$20. Goldman coverage for the Organon & Co (OGN) stock in a research note released on November 03, 2023 offered a Neutral rating with a price target of $16. Barclays was of a view on September 21, 2023 that the stock is Overweight, while Raymond James gave the stock Outperform rating on March 16, 2023, issuing a price target of $33. BofA Securities on their part issued Underperform rating on October 14, 2022.
